MedPath

Bosnalijek d.d.

Bosnalijek d.d. logo
🇧🇦Bosnia and Herzegovina
Ownership
Private
Established
1951-01-10
Employees
501
Market Cap
-
Website
http://bosnalijek.com

Clinical Trials

3

Active:0
Completed:2

Trial Phases

2 Phases

Phase 2:1
Phase 3:2

Drug Approvals

5

PHILIPPINES:5

Drug Approvals

Rinobact Spray

Approval Date
Jul 14, 2025
PHILIPPINES

Lysobact Complete Spray

Approval Date
Jul 14, 2025
PHILIPPINES

Rinobact P Spray

Approval Date
Jul 14, 2025
PHILIPPINES

Lysobact P Spray

Approval Date
Jul 14, 2025
PHILIPPINES

Lynase

Approval Date
Jul 14, 2025
PHILIPPINES

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 3
2 (66.7%)
Phase 2
1 (33.3%)

Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection

Phase 2
Completed
Conditions
COVID-19 Infection
Interventions
Drug: The standard of care
First Posted Date
2020-05-05
Last Posted Date
2020-12-24
Lead Sponsor
Bosnalijek D.D
Target Recruit Count
120
Registration Number
NCT04374032
Locations
🇧🇦

Clinical Center University of Sarajevo, Sarajevo, Sarajevo Canton, Bosnia and Herzegovina

🇧🇦

University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina

🇧🇦

University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina

and more 2 locations

A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS

Phase 3
Terminated
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Drug: INF beta-1a
First Posted Date
2017-09-14
Last Posted Date
2024-08-13
Lead Sponsor
Bosnalijek D.D
Target Recruit Count
301
Registration Number
NCT03283397
Locations
🇹🇷

Kocaeli University, Faculty of Medicine, Department of Neurology, Kocaeli, Turkey

Efficacy and Safety of the Lysobact Complete Spray®, Tantum Verde® and Pharyngal® Oromucosal Spray in the Treatment of Acute Sore Throat

Phase 3
Completed
Conditions
Sore Throat
Interventions
Drug: Pharyngal® Oromucosal Spray
Drug: Lysobact Complete Sprey
Drug: Placebo
First Posted Date
2017-09-13
Last Posted Date
2021-03-16
Lead Sponsor
Bosnalijek D.D
Target Recruit Count
346
Registration Number
NCT03282045
Locations
🇧🇦

University Clinical Center of the Republic of Srpska, ENT Clinic, Banja Luka, Bosnia and Herzegovina, Banja Luka, Bosnia and Herzegovina

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.